

# David M Kent

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6800383/publications.pdf>

Version: 2024-02-01

173  
papers

8,814  
citations

47409

49  
h-index

56606

87  
g-index

182  
all docs

182  
docs citations

182  
times ranked

10926  
citing authors

#	ARTICLE	IF	CITATIONS
1	Stratifying Future Stroke Risk with Incidentally Discovered White Matter Disease Severity and Covert Brain Infarct Site. <i>Cerebrovascular Diseases</i> , 2023, 52, 117-122.	0.8	2
2	An Electronic Health Recordâ€Compatible Model to Predict Personalized Treatment Effects From the Diabetes Prevention Program: A Cross-Evidence Synthesis Approach Using Clinical Trial and Real-World Data. <i>Mayo Clinic Proceedings</i> , 2022, 97, 703-715.	1.4	0
3	All-cause mortality as the primary endpoint for the GRAIL/National Health Service England multi-cancer screening trial. <i>Journal of Medical Screening</i> , 2022, 29, 3-6.	1.1	8
4	Validation of a United Kingdom Model to Predict Mortality in Incident Dialysis Patients in the Dialysis Outcomes and Practice Patterns Study Cohort: Introduction of a Clinical Risk Score. <i>Kidney Medicine</i> , 2022, 4, 100417.	1.0	0
5	Generalizability of Cardiovascular Disease Clinical Prediction Models: 158 Independent External Validations of 104 Unique Models. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, 101161CIRCOUTCOMES121008487.	0.9	21
6	External Validation of the FREEDOM Score for Individualized Decision Making Between CABG and PCI. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1458-1473.	1.2	3
7	Treatment Effects in Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovaleâ€Reply. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1403.	3.8	0
8	Risk Factors for Silent Brain Infarcts and White Matter Disease in a Real-World Cohort Identified by Natural Language Processing. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1114-1122.	1.4	2
9	Does poor methodological quality of prediction modeling studies translate to poor model performance? An illustration in traumatic brain injury. <i>Diagnostic and Prognostic Research</i> , 2022, 6, 8.	0.8	7
10	Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained. <i>Acta Diabetologica</i> , 2021, 58, 707-722.	1.2	2
11	Abstract P57: Risk Factors for Incidentally Discovered Silent Brain Infarcts and White Matter Disease in a Real World Cohort Identified by Artificial Intelligence. <i>Stroke</i> , 2021, 52, .	1.0	2
12	The cumulative incidence of dysphagia and dysphagiaâ€free survival in persons diagnosed with amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2021, 64, 83-86.	1.0	8
13	Agreement between neuroimages and reports for natural language processing-based detection of silent brain infarcts and white matter disease. <i>BMC Neurology</i> , 2021, 21, 189.	0.8	10
14	Association of Silent Cerebrovascular Disease Identified Using Natural Language Processing and Future Ischemic Stroke. <i>Neurology</i> , 2021, 97, e1313-e1321.	1.5	25
15	External Validations of Cardiovascular Clinical Prediction Models: A Large-Scale Review of the Literature. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007858.	0.9	32
16	External Validation of the SYNTAXâScoreâII 2020. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1227-1238.	1.2	30
17	COVID outcome prediction in the emergency department (COPE): using retrospective Dutch hospital data to develop simple and valid models for predicting mortality and need for intensive care unit admission in patients who present at the emergency department with suspected COVID-19. <i>BMJ Open</i> , 2021, 11, e051468.	0.8	12
18	Large-scale validation of the prediction model risk of bias assessment Tool (PROBAST) using a short form: high risk of bias models show poorer discrimination. <i>Journal of Clinical Epidemiology</i> , 2021, 138, 32-39.	2.4	29

#	ARTICLE	IF	CITATIONS
19	Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2277.	3.8	92
20	937. A Clinical Prediction Tool to Determine Risk of Infection in the First Year Following Heart Transplant. <i>Open Forum Infectious Diseases</i> , 2021, 8, S560-S561.	0.4	0
21	Re: Selecting Optimal Subgroups for Treatment Using Many Covariates. <i>Epidemiology</i> , 2020, 31, e30-e31.	1.2	2
22	Developing a cancer-specific trigger tool to identify treatment-related adverse events using administrative data. <i>Cancer Medicine</i> , 2020, 9, 1462-1472.	1.3	10
23	Prehospital Triage Strategies for the Transportation of Suspected Stroke Patients in the United States. <i>Stroke</i> , 2020, 51, 3310-3319.	1.0	20
24	Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation. <i>Lancet, The</i> , 2020, 396, 1399-1412.	6.3	120
25	Fear of Coronavirus Disease 2019—An Emerging Cardiac Risk. <i>JAMA Cardiology</i> , 2020, 5, 981.	3.0	23
26	Can Clinical Predictive Models Identify Patients Who Should Not Receive TAVR? A Systematic Review. <i>Structural Heart</i> , 2020, 4, 295-299.	0.2	5
27	Why clinical trials may not help patients make treatment decisions: results from focus group discussions with 22 patients. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 651-658.	0.6	0
28	The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. <i>Annals of Internal Medicine</i> , 2020, 172, 35.	2.0	203
29	The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration. <i>Annals of Internal Medicine</i> , 2020, 172, W1.	2.0	83
30	The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. <i>Annals of Internal Medicine</i> , 2020, 172, 776.	2.0	4
31	Clinical Predictive Models of Sudden Cardiac Arrest: A Survey of the Current Science and Analysis of Model Performances. <i>Journal of the American Heart Association</i> , 2020, 9, e017625.	1.6	29
32	Predictive approaches to heterogeneous treatment effects: a scoping review. <i>BMC Medical Research Methodology</i> , 2020, 20, 264.	1.4	32
33	Predictably unequal: understanding and addressing concerns that algorithmic clinical prediction may increase health disparities. <i>Npj Digital Medicine</i> , 2020, 3, 99.	5.7	106
34	Risk of Paradoxical Embolism (RoPE)—Estimated Attributable Fraction Correlates With the Benefit of Patent Foramen Ovale Closure. <i>Stroke</i> , 2020, 51, 3119-3123.	1.0	41
35	When predictions are used to allocate scarce health care resources: three considerations for models in the era of Covid-19. <i>Diagnostic and Prognostic Research</i> , 2020, 4, 11.	0.8	5
36	Prior Stroke in PFO Patients Is Associated With Both PFO-Related and -Unrelated Factors. <i>Frontiers in Neurology</i> , 2020, 11, 503.	1.1	2

#	ARTICLE	IF	CITATIONS
37	Precision Health Analytics With Predictive Analytics and Implementation Research. Journal of the American College of Cardiology, 2020, 76, 306-320.	1.2	25
38	Chronic Conditions in Advanced Cardiac Disease: A Cluster Analysis of Transcatheter Aortic Valve Replacement (TAVR)-Treated Patients. Journal of General Internal Medicine, 2020, 35, 2231-2233.	1.3	0
39	Practice advisory update summary: Patent foramen ovale and secondary stroke prevention. Neurology, 2020, 94, 876-885.	1.5	123
40	Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke. JAMA Neurology, 2020, 77, 878.	4.5	105
41	Stakeholder engagement in methodological research: Development of a clinical decision support tool. Journal of Clinical and Translational Science, 2020, 4, 133-140.	0.3	4
42	Association between cancer-specific adverse event triggers and mortality: A validation study. Cancer Medicine, 2020, 9, 4447-4459.	1.3	4
43	Assessment of the impact of EHR heterogeneity for clinical research through a case study of silent brain infarction. BMC Medical Informatics and Decision Making, 2020, 20, 60.	1.5	26
44	Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargeting. Journal of Clinical Epidemiology, 2019, 114, 72-83.	2.4	53
45	3385 TARGETING DIABETES PREVENTION PROGRAMS: INDIVIDUAL RISK-BASED HEALTH ECONOMIC ANALYSIS. Journal of Clinical and Translational Science, 2019, 3, 155-156.	0.3	0
46	Patients' responses to incidentally discovered silent brain infarcts - a qualitative study. Journal of Patient-Reported Outcomes, 2019, 3, 23.	0.9	5
47	The use of patient-specific equipoise to support shared decision-making for clinical care and enrollment into clinical trials. Journal of Clinical and Translational Science, 2019, 3, 27-36.	0.3	4
48	Clinical Prediction Models for Valvular Heart Disease. Journal of the American Heart Association, 2019, 8, e011972.	1.6	12
49	Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off. Clinical Breast Cancer, 2019, 19, 259-267.e1.	1.1	22
50	Early withdrawal of life support after resuscitation from cardiac arrest is common and may result in additional deaths. Resuscitation, 2019, 139, 308-313.	1.3	77
51	Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency. Health Affairs, 2019, 38, 60-67.	2.5	8
52	Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk. Stroke, 2019, 50, 95-100.	1.0	9
53	Natural Language Processing for the Identification of Silent Brain Infarcts From Neuroimaging Reports. JMIR Medical Informatics, 2019, 7, e12109.	1.3	40
54	Developing a cancer-specific trigger tool to identify adverse events using administrative data.. Journal of Clinical Oncology, 2019, 37, 238-238.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Patient Variability Seldom Assessed in Cost-effectiveness Studies. <i>Medical Decision Making</i> , 2018, 38, 487-494.	1.2	16
56	Accuracy of Prediction Instruments for Diagnosing Large Vessel Occlusion in Individuals With Suspected Stroke: A Systematic Review for the 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. <i>Stroke</i> , 2018, 49, e111-e122.	1.0	184
57	Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model. <i>American Journal of Medicine</i> , 2018, 131, 676-683.e2.	0.6	3
58	The proposed $\hat{\tau}$ concordance-statistic for benefit <sup>TM</sup> provided a useful metric when modeling heterogeneous treatment effects. <i>Journal of Clinical Epidemiology</i> , 2018, 94, 59-68.	2.4	55
59	2020 The clinical implications of a positive prostate cancer screen in patients undergoing a cardiac transplant evaluation. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 48-48.	0.3	0
60	Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. <i>BMJ: British Medical Journal</i> , 2018, 363, k4245.	2.4	234
61	Variation in Sedation and Neuromuscular Blockade Regimens on Outcome After Cardiac Arrest*. <i>Critical Care Medicine</i> , 2018, 46, e975-e980.	0.4	34
62	Big Data and Predictive Analytics. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 27.	3.8	185
63	Evaluation of person-level heterogeneity of treatment effects in published multiperson N-of-1 studies: systematic review and reanalysis. <i>BMJ Open</i> , 2018, 8, e017641.	0.8	16
64	Population-Based Validation of a Clinical Prediction Model for Congenital Diaphragmatic Hernias. <i>Journal of Pediatrics</i> , 2018, 201, 160-165.e1.	0.9	26
65	Risk-Targeted Lung Cancer Screening. <i>Annals of Internal Medicine</i> , 2018, 168, 161.	2.0	85
66	Effects of Race Are Rarely Included in Clinical Prediction Models for Cardiovascular Disease. <i>Journal of General Internal Medicine</i> , 2018, 33, 1429-1430.	1.3	17
67	Risk-Targeted Lung Cancer Screening. <i>Annals of Internal Medicine</i> , 2018, 169, 200.	2.0	1
68	Clinicians <sup>TM</sup> perspectives on incidentally discovered silent brain infarcts $\hat{\tau}$ A qualitative study. <i>PLoS ONE</i> , 2018, 13, e0194971.	1.1	11
69	Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models. <i>Medical Decision Making</i> , 2017, 37, 790-801.	1.2	9
70	Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. <i>JAMA Neurology</i> , 2017, 74, 1319.	4.5	21
71	Role of Secondary Prophylaxis with Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2017, 4, S712-S712.	0.4	0
72	Biases in Individualized Cost-effectiveness Analysis: Influence of Choices in Modeling Short-Term, Trial-Based, Mortality Risk Reduction and Post-Trial Life Expectancy. <i>Medical Decision Making</i> , 2017, 37, 770-778.	1.2	4

#	ARTICLE	IF	CITATIONS
73	Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2017, 65, 2000-2007.	2.9	41
74	Regional Validation and Recalibration of Clinical Predictive Models for Patients With Acute Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	19
75	Race and Ethnicity. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	25
76	A Dynamic Predictive Model for Progression of CKD. <i>American Journal of Kidney Diseases</i> , 2017, 69, 514-520.	2.1	78
77	Tufts PACE Clinical Predictive Model Registry: update 1990 through 2015. <i>Diagnostic and Prognostic Research</i> , 2017, 1, 20.	0.8	39
78	Response to Comment on Shahrzad et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? <i>Diabetes Care</i> 2016;38: e145-e146. <i>Diabetes Care</i> , 2016, 39, e228-e228.	4.3	0
79	Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. <i>International Journal of Epidemiology</i> , 2016, 45, dyw118.	0.9	89
80	Field Synopsis of Sex in Clinical Prediction Models for Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, S8-15.	0.9	9
81	Sex Versus Gender in Recurrent Events Following Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1371-1372.	1.2	0
82	Development and Validation of a Predictive Model for Short- and Medium-Term Hospital Readmission Following Heart Valve Surgery. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	17
83	Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 684-692.e3.	0.2	15
84	Prediabetes Risk in Adult Americans According to a Risk Test. <i>JAMA Internal Medicine</i> , 2016, 176, 1861.	2.6	14
85	Practice advisory: Recurrent stroke with patent foramen ovale (update of practice parameter) [RETIRED]. <i>Neurology</i> , 2016, 87, 815-821.	1.5	114
86	Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	25
87	Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence. <i>International Journal of Epidemiology</i> , 2016, 45, dyw125.	0.9	66
88	Field Synopsis of the Role of Sex in Stroke Prediction Models. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	11
89	Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A 1c Targets?. <i>Diabetes Care</i> , 2016, 39, e145-e146.	4.3	6
90	Device Closure of Patent Foramen Ovale After Stroke. <i>Journal of the American College of Cardiology</i> , 2016, 67, 907-917.	1.2	183

#	ARTICLE	IF	CITATIONS
91	Hospitalsâ€™ Patterns of Use of Noninvasive Ventilation in Patients With Asthma Exacerbation. <i>Chest</i> , 2016, 149, 729-736.	0.4	16
92	In-hospital measurement of left ventricular ejection fraction and one-year outcomes in acute coronary syndromes: results from the IMMEDIATE Trial. <i>Cardiovascular Ultrasound</i> , 2015, 14, 29.	0.5	20
93	The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk. <i>Annals of Internal Medicine</i> , 2015, 162, 866-867.	2.0	15
94	Three simple rules to ensure reasonably credible subgroup analyses. <i>BMJ, The</i> , 2015, 351, h5651.	3.0	157
95	Toward a Modern Era in Clinical Prediction: The TRIPOD Statement for Reporting Prediction Models. <i>American Journal of Kidney Diseases</i> , 2015, 65, 530-533.	2.1	9
96	The RoPE Score and Right-to-Left Shunt Severity by Transcranial Doppler in the CODICIA Study. <i>Cerebrovascular Diseases</i> , 2015, 40, 52-58.	0.8	31
97	Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis. <i>European Heart Journal</i> , 2015, 36, 2381-2389.	1.0	98
98	Myocardial Infarction, Stroke, and Mortality in cART-Treated HIV Patients on Statins. <i>AIDS Patient Care and STDs</i> , 2015, 29, 307-313.	1.1	19
99	Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. <i>BMJ, The</i> , 2015, 350, h454-h454.	3.0	101
100	Prevention of Recurrent Stroke in Patients with Patent Foramen Ovale. <i>Neurologic Clinics</i> , 2015, 33, 491-500.	0.8	2
101	Clinical Prediction Models for Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 368-375.	0.9	79
102	Development and validation of a simplified Strokeâ€™Thrombolytic Predictive Instrument. <i>Neurology</i> , 2015, 85, 942-949.	1.5	25
103	A predictive model to identify patients with suspected acute coronary syndromes at high risk of cardiac arrest or in-hospital mortality: An IMMEDIATE Trial sub-study. <i>IJC Heart and Vasculature</i> , 2015, 9, 37-42.	0.6	0
104	All Else Being Equal, Men and Women Are Still Not the Same. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 317-320.	0.9	10
105	Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (<scp>BPH</scp>). <i>BJU International</i> , 2015, 115, 308-318.	1.3	40
106	Controversies in Cardioembolic Stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2015, 17, 358.	0.4	11
107	Determinants of antithrombotic choice for patent foramen ovale in cryptogenic stroke. <i>Neurology</i> , 2014, 83, 1954-1957.	1.5	7
108	Using Internally Developed Risk Models to Assess Heterogeneity in Treatment Effects in Clinical Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 163-169.	0.9	70

#	ARTICLE	IF	CITATIONS
109	Recurrent stroke predictors differ in medically treated patients with pathogenic vs other PFOs. <i>Neurology</i> , 2014, 83, 221-226.	1.5	103
110	Can the Learning Health Care System Be Educated With Observational Data?. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 129.	3.8	61
111	A Framework for Crafting Clinical Practice Guidelines that are Relevant to the Care and Management of People with Multimorbidity. <i>Journal of General Internal Medicine</i> , 2014, 29, 670-679.	1.3	125
112	Multimorbidity and Evidence Generation. <i>Journal of General Internal Medicine</i> , 2014, 29, 653-660.	1.3	54
113	Evidence-Based Medicine and the Hard Problem of Multimorbidity. <i>Journal of General Internal Medicine</i> , 2014, 29, 552-553.	1.3	51
114	Predictors of Recurrent Events in Patients With Cryptogenic Stroke and Patent Foramen Ovale Within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Patent Foramen Ovale) Trial. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 913-920.	1.1	55
115	Assessment of the Relative Effectiveness and Tolerability of Treatments of Type 2 Diabetes Mellitus: A Network Meta-analysis. <i>Clinical Therapeutics</i> , 2014, 36, 1443-1453.e9.	1.1	18
116	Transesophageal Echocardiography in Cryptogenic Stroke and Patent Foramen Ovale. <i>Circulation: Cardiovascular Imaging</i> , 2014, 7, 125-131.	1.3	58
117	A Nomogram to Predict Major Complications After Hip and Knee Arthroplasty. <i>Journal of Arthroplasty</i> , 2014, 29, 1457-1462.	1.5	39
118	Off-hour presentation and outcomes in patients with acute ischemic stroke: A systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2014, 25, 394-400.	1.0	55
119	Still No Closure on the Question of PFO Closure. <i>New England Journal of Medicine</i> , 2013, 368, 1152-1153.	13.9	45
120	The Risk of Paradoxical Embolism (RoPE) Study: Initial Description of the Completed Database. <i>International Journal of Stroke</i> , 2013, 8, 612-619.	2.9	51
121	Potentially Large yet Uncertain Benefits. <i>Stroke</i> , 2013, 44, 2640-2643.	1.0	45
122	Response to Letter Regarding Article, "Potentially Large yet Uncertain Benefits: A Meta-analysis of Patent Foramen Ovale Closure Trials". <i>Stroke</i> , 2013, 44, e234.	1.0	0
123	An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. <i>Neurology</i> , 2013, 81, 619-625.	1.5	468
124	Neuroimaging Findings in Cryptogenic Stroke Patients With and Without Patent Foramen Ovale. <i>Stroke</i> , 2013, 44, 675-680.	1.0	66
125	Towards an epidemiology of the known unknowns in cryptogenic stroke: Figure 1. <i>Heart</i> , 2012, 98, 1114-1116.	1.2	2
126	How to Integrate Multiple Comorbidities in Guideline Development. <i>Proceedings of the American Thoracic Society</i> , 2012, 9, 274-281.	3.5	57



#	ARTICLE	IF	CITATIONS
127	Prognostic Models for Older Adults. JAMA - Journal of the American Medical Association, 2012, 307, 1911.	3.8	3
128	Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention. Stroke, 2012, 43, 422-431.	1.0	128
129	Percutaneous Closure of Patent Foramen Ovale. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 414-415.	0.9	4
130	Risk Models and Patient-Centered Evidence. JAMA - Journal of the American Medical Association, 2012, 307, 1585.	3.8	37
131	Personalised medicine: not just in our genes. BMJ, The, 2012, 344, e2161-e2161.	3.0	39
132	Abstract 3430: Superficial and Large Infarcts on Neuroimaging in Patients with Cryptogenic Stroke are Associated with the Presence or Absence of Patent Foramen Ovale. Stroke, 2012, 43, .	1.0	0
133	Random Treatment Assignment Using Mathematical Equipoise for Comparative Effectiveness Trials. Clinical and Translational Science, 2011, 4, 10-16.	1.5	7
134	A CTSA Agenda to Advance Methods for Comparative Effectiveness Research. Clinical and Translational Science, 2011, 4, 188-198.	1.5	28
135	The Risk of Paradoxical Embolism (RoPE) Study: Developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke. Trials, 2011, 12, 185.	0.7	95
136	Index Event Bias as an Explanation for the Paradoxes of Recurrence Risk Research. JAMA - Journal of the American Medical Association, 2011, 305, 822.	3.8	248
137	Rethinking trial strategies for stroke and patent foramen ovale. Current Opinion in Neurology, 2010, 23, 73-78.	1.8	13
138	Aggregating and Disaggregating Patients in Clinical Trials and Their Subgroup Analyses. Annals of Internal Medicine, 2010, 153, 51.	2.0	13
139	The Empirical Basis for Determinations of Medical Futility. Journal of General Internal Medicine, 2010, 25, 1083-1089.	1.3	56
140	Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials, 2010, 11, 85.	0.7	391
141	Is Patent Foramen Ovale a Modifiable Risk Factor for Stroke Recurrence?. Stroke, 2010, 41, S26-30.	1.0	68
142	Therapeutic Innovations, Diminishing Returns, and Control Rate Preservation. JAMA - Journal of the American Medical Association, 2009, 302, 2254.	3.8	25
143	Are Unadjusted Analyses of Clinical Trials Inappropriately Biased Toward the Null?. Stroke, 2009, 40, 672-673.	1.0	18
144	Patent Foramen Ovale in Cryptogenic Stroke. Stroke, 2009, 40, 2349-2355.	1.0	326

#	ARTICLE	IF	CITATIONS
145	Against pragmatism: on efficacy, effectiveness and the real world. <i>Trials</i> , 2009, 10, 48.	0.7	42
146	Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. <i>Lancet, The</i> , 2009, 373, 911-918.	6.3	215
147	Competing risk and heterogeneity of treatment effect in clinical trials. <i>Trials</i> , 2008, 9, 30.	0.7	43
148	A Percutaneous Coronary Interventionâ€“Thrombolytic Predictive Instrument to Assist Choosing Between Immediate Thrombolytic Therapy Versus Delayed Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2008, 101, 790-795.	0.7	8
149	Are â€œtreatmentâ€ bare metal stents superior to â€œcontrolâ€ bare metal stents? A meta-analytic approach. <i>American Heart Journal</i> , 2008, 155, 624-629.e2.	1.2	2
150	The gender effect in stroke thrombolysis. <i>Neurology</i> , 2008, 71, 1080-1083.	1.5	66
151	Patent foramen ovale and cryptogenic stroke. <i>New England Journal of Medicine</i> , 2008, 358, 1519-20; author reply 1520-1.	13.9	12
152	Limitations of Applying Summary Results of Clinical Trials to Individual Patients. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 1209.	3.8	430
153	Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1959-1965.	3.0	154
154	Comparison of Mortality Benefit of Immediate Thrombolytic Therapy Versus Delayed Primary Angioplasty for Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2007, 99, 1384-1388.	0.7	24
155	When Averages Hide Individual Differences in Clinical Trials. <i>American Scientist</i> , 2007, 95, 60.	0.1	42
156	Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. <i>BMC Medical Research Methodology</i> , 2006, 6, 18.	1.4	179
157	Sex-Based Differences in the Effect of Intra-Arterial Treatment of Stroke. <i>Stroke</i> , 2006, 37, 2322-2325.	1.0	82
158	Differences in Response to Reperfusion Therapies in Acute Stroke Between Men and Women: Mediated by Sex or by Chance?. <i>Stroke</i> , 2006, 37, 2878-2879.	1.0	4
159	Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window?. <i>Stroke</i> , 2006, 37, 2963-2969.	1.0	26
160	The Strokeâ€“Thrombolytic Predictive Instrument. <i>Stroke</i> , 2006, 37, 2957-2962.	1.0	148
161	Sex-Based Differences in Response to Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke. <i>Stroke</i> , 2005, 36, 62-65.	1.0	231
162	Reporting Clinical Trial Results To Inform Providers, Payers, And Consumers. <i>Health Affairs</i> , 2005, 24, 1571-1581.	2.5	81

#	ARTICLE	IF	CITATIONS
163	“Clinical-CT Mismatch” and the Response to Systemic Thrombolytic Therapy in Acute Ischemic Stroke. <i>Stroke</i> , 2005, 36, 1695-1699.	1.0	51
164	Clinical Trials in Sub-Saharan Africa and Established Standards of Care. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 237.	3.8	31
165	In Acute Ischemic Stroke, Are Asymptomatic Intracranial Hemorrhages Clinically Innocuous?. <i>Stroke</i> , 2004, 35, 1141-1146.	1.0	37
166	New and Dis-Improved: On the Evaluation and Use of Less Effective, Less Expensive Medical Interventions. <i>Medical Decision Making</i> , 2004, 24, 281-286.	1.2	24
167	Suitable Monitoring Approaches to Antiretroviral Therapy in Resource-Poor Settings: Setting the Research Agenda. <i>Clinical Infectious Diseases</i> , 2003, 37, S13-S24.	2.9	26
168	Testing Therapies Less Effective than the Best Current Standard: Ethical Beliefs in an International Sample of Researchers. <i>American Journal of Bioethics</i> , 2003, 3, 28-33.	0.5	4
169	Are Some Patients Likely to Benefit From Recombinant Tissue-Type Plasminogen Activator for Acute Ischemic Stroke Even Beyond 3 Hours From Symptom Onset?. <i>Stroke</i> , 2003, 34, 464-467.	1.0	49
170	An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. <i>American Journal of Medicine</i> , 2002, 113, 104-111.	0.6	58
171	Is primary angioplasty for some as good as primary angioplasty for all?. <i>Journal of General Internal Medicine</i> , 2002, 17, 887-894.	1.3	41
172	The Framingham scores overestimated the risk for coronary heart disease in Japanese, Hispanic, and Native American cohorts. <i>ACP Journal Club</i> , 2002, 136, 36.	0.1	1
173	Review: Functional testing for restenosis after PTCA has limited value. <i>ACP Journal Club</i> , 2001, 135, 34.	0.1	0